Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight loss pill shows promise in major trial

NCT ID NCT05564117

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a daily 25 mg semaglutide pill in 307 adults with overweight or obesity over 64 weeks. Participants taking the drug lost more weight than those on placebo, with many achieving at least 5% body weight reduction. The pill offers a convenient alternative to injections for weight management.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide
What this could lead to
If successful, this could provide a convenient daily pill for significant weight loss in people with overweight or obesity.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to everyone. Side effects like nausea or vomiting are possible, and weight regain may occur after stopping treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

307 people

The number who actually took part.

Started

Oct 2022

Finished

May 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study * Male or female, age greater than or equal to 18 years at the time of signing informed consent * Body mass index (BMI) of * Greater than or equal to 27.0 kg/m\^2 with the presence of at least one of the following weight-related complications (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular (CV) disease OR * Greater than or equal to 30.0 kg/m\^2 * History of at least one self-reported unsuccessful dietary effort to lose body weight Exclusion Criteria: * A self-reported change in body weight greater than 5 kg (11 pound \[lbs\]) within 90 days before screening irrespective of medical records * HbA1c greater than or equal to 6.5 percent (48 mmol/mol) as measured by the central laboratory at screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

Contacts and locations

Locations

  • Accellacare

    Wilmington, North Carolina, 28401, United States

  • Beata Miklaszewicz&Dariusz Dabrowski "CARDIAMED" s.j.

    Legnica, Lower Silesian Voivodeship, 59-220, Poland

  • Centrum Zdrowia Metabolicznego

    Poznan, Wielkopolskie Voivodeship, 60-589, Poland

  • Diabetologische Gemeinschaftspraxis Dr. Staudenmeyer und Dr. Schiwietz

    Lingen, 49808, Germany

  • ETG Lublin

    Lublin, Lublin Voivodeship, 20-412, Poland

  • ETG Siedlce

    Siedlce, Masovian Voivodeship, 08-110, Poland

  • ETG Warszawa Sp. z o.o.

    Warsaw, Masovian Voivodeship, 02-677, Poland

  • East West Medical Research Institute_Honolulu

    Honolulu, Hawaii, 96814, United States

  • FDRC

    Costa Mesa, California, 92627, United States

  • G.A. Research Associates Ltd.

    Moncton, New Brunswick, E1G 1A7, Canada

  • Gabinet Leczenia Otylosci i Chorob Dietozaleznych

    Bialystok, Podlaskie Voivodeship, 15-281, Poland

  • InnoDiab Forschung GmbH

    Essen, 45136, Germany

  • MZM Praxis Drs. Erlinger

    Stuttgart, 70378, Germany

  • MedicalCenter am Clemenshospital - Schwerpunktpraxis für Diabetologie und Ernährungsmedizin

    Münster, 48153, Germany

  • Praxis Dr. med. Wenzl-Bauer

    Rehlingen-Siersburg, 66780, Germany

  • Praxis für Prävention und Therapie, Drs Jacob

    Villingen-Schwenningen, 78048, Germany

  • RED-Institut für medizinische Forschung und Fortbildung GmbH

    Oldenburg in Holstein, 23758, Germany

  • Selma Medical Associates

    Winchester, Virginia, 22601, United States

  • UT Southwestern Med Cntr

    Dallas, Texas, 75390-9302, United States

  • Univsty Of AL At Birmingham

    Birmingham, Alabama, 35294, United States

  • Washington Cntr Weight Mgmt

    Arlington, Virginia, 22206, United States

  • Wharton Med Clin Trials

    Hamilton, Ontario, L8L 5G8, Canada

  • Zentrum für klinische Studien Allgäu Oberschwaben

    Wangen, 88239, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.